ELISpot

Human CD8α^+/IFN-γ

Catalog Number EL3094

For the quantitative determination of the frequency of CD8α^+ cells releasing human IFN-γ.

This package insert must be read in its entirety before using this product.

TABLE OF CONTENTS

Contents   Page

MANUFACTURED AND DISTRIBUTED BY:

R&D Systems, Inc.   TELEPHONE: (800) 343-7475
614 McKinley Place NE   (612) 379-2956
Minneapolis, MN 55413   FAX: (612) 656-4400
United States of America   E-MAIL: info@RnDSystems.com

DISTRIBUTED BY:

R&D Systems Europe, Ltd.
19 Barton Lane   TELEPHONE: +44 (0)1235 529449
Abingdon Science Park   FAX: +44 (0)1235 533420
Abingdon, OX14 3NB   E-MAIL: info@RnDSystems.co.uk
United Kingdom

R&D Systems China Co. Ltd.
24A1 Hua Min Empire Plaza   TELEPHONE: +86 (21) 52380373
726 West Yan An Road   FAX: +86 (21) 52371001
Shanghai PRC 200050   E-MAIL: info@RnDSystemsChina.com.cn

INTRODUCTION

Human CD8 is a 65 - 70 kDa homo- or heterodimeric glycoprotein best known for its expression on the surface of a mature T cell subset (1, 2). Linked by disulfide bonds, the two chains which comprise the CD8 dimer form either an α - α or an α - β combination, with individual α and β chains arising from two distinct, but closely related genes (1, 3). Both the α and β chains are type I transmembrane glycoproteins and both are composed of an N-terminal V-type Ig-like domain which is followed by a flexible hinge region, a transmembrane segment, and a short cytoplasmic tail (4, 5). The mature α chain is 214 amino acids (aa) in length with a predicted molecular weight of 23.5 kDa, while the mature β chain is somewhat shorter at 189 aa with a predicted molecular weight of 22.9 kDa (4, 5). Alpha to beta, aa sequence identity in the Ig-like domain is only 17% (2). The CD8$\alpha\beta$ heterodimer is particularly prevalent on peripheral blood T cells (1, 6), while the CD8$\alpha\alpha$ homodimer is expressed predominantly by tissue-associated T cells (6, 7), NK cells (8) and select dendritic cells (9). The CD8$\alpha\beta$ heterodimer functions as a TCR co-receptor on MHC Class-I restricted thymocytes and T cells, while the CD8$\alpha\alpha$ homodimer is a TCR modulator that rescues lymphocytes from cell death while promoting differentiation (10).

Human interferon-gamma (IFN-γ) is a 34 - 45 kDa, non-disulfide linked homodimeric glycoprotein that plays a crucial role in cell-based immunity (11 - 13). It is synthesized as a 17 - 25 kDa, 146 aa mature protein, and often undergoes considerable post-translational processing, resulting in multiple proteolytic isoforms (14, 15). In the amino-terminus, a 3 aa truncation occurs, with the substitution of a pyroglutamate as the initial amino acid (14, 15). In the C-terminus, multiple truncations of up to 16 aa occur, resulting in molecules of varying bioactivity (15 - 17). Functionally, the N-terminus is associated with receptor binding (aa 12 - 20) (18, 19), while the C-terminus is associated with nuclear localization (20), heparin-binding (21), and the first step of receptor-ligand interaction (22). Notably, although the molecule circulates as a homodimer, the actual functional unit at the receptor interface is a 72 kDa tetramer (23). Cells reported to express IFN-γ include dendritic epidermal/$\gamma\delta$ T cells (24), keratinocytes (25), peripheral blood $\gamma\delta$ T cells (26), mast cells (27), neurons (28), CD8[+] T cells (29), macrophages (30), B cells (31), neutrophils (32), NK cells (33) and CD4[+] T cells (34).

The ELISpot assay is particularly well suited for the identification of IFN-γ secreting cells. Given that *in vivo* pools of IFN-γ are suggested to be sequestered by extracellular matrix (35), the degree to which IFN-γ secretion changes may be incorrectly estimated in body fluid assays (36). By quantifying the number of increasing/decreasing IFN-γ secreting cells, a clearer picture may emerge relative to the predisposition to cell-mediated immunity (36, 37). ELISpot assays are well suited for studying immune responses to various treatments and therapies and have been used for the quantitation of antigen-specific CD4$^+$ and/or CD8$^+$ T cell responses. Other methods for assessment of antigen-specific T cell responses, such as chromium release assay with quantitation by limiting dilution are tedious and require previous *in vitro* expansion of T cells for several days. These assays typically are not suitable for measuring infrequent T cell responses that occur at less than 1 in 1000. ELISpot assays are highly reproducible and sensitive and can be used to measure responses with frequencies well below 1 in 100,000. ELISpot assays do not require prior *in vitro* expansion of T cells and are suitable for high-throughput analysis using only small volumes of primary cells. As such, ELISpot assays are useful tools for research in vaccine development and for the monitoring of various clinical trials.

PRINCIPLE OF THE ASSAY

The enzyme-linked immunospot (ELISpot) assay was originally developed for the detection of individual B cells secreting antigen-specific antibodies (38, 39). This method has since been adapted for the detection of a selected cell type secreting specific cytokines or other antigens (40, 41). ELISpot assays employ the quantitative sandwich enzyme-linked immunosorbent assay (ELISA) technique. PVDF (polyvinylidene difluoride)-backed microplates are coated with both anti-human CD8α^+ and anti-human IFN-γ monoclonal antibodies. Cells are added to the plate and incubated for a short period of time to capture CD8α^+ cells. After that, plates are washed to remove unbound non-CD8α^+ cells. The ELISpot plate with CD8α^+-enriched cells is placed into a 37° C CO_2 incubator for a specified period of time. During the incubation, anti-human IFN-γ antibodies capture IFN-γ secreted primarily by CD8α^+ cells. After washing away any cells and unbound substances, a biotinylated polyclonal antibody specific for human IFN-γ is added to the wells. Following a wash to remove any unbound biotinylated antibody, alkaline-phosphatase conjugated to streptavidin is added. Unbound enzyme is subsequently removed by washing and a substrate solution (BCIP/NBT) is added. A blue-black colored precipitate forms at the sites of cytokine localization and appear as spots, with each individual spot representing an individual IFN-γ secreting cell. The spots can be counted with an automated ELISpot reader system or manually using a stereomicroscope.

ELISpot SCHEMATIC

Legend:

- (+) CD8α⁺ Cells
- (−) CD8α⁻ Cells
- Anti-CD8α⁺ Antibody
- Anti-IFN-γ Antibody
- Secreted Analyte
- B Biotinylated Antibody
- AP/SA Alkaline Phosphatase Conjugated Streptavidin
- Color Product

1. Incubate cell solution for 1 hour at room temperature and then wash.

2. CD8α⁺ cells are bound by CD8α⁺ capture antibodies. These cells can then be stimulated to release IFN-γ.

3. Incubate IFN-γ-secreting cells in an antibody coated well.

4. Secreted IFN-γ is captured by the immobilized IFN-γ capture antibody.

5. Incubate with biotinylated anti-IFN-γ antibody.

6. Incubate with alkaline phosphatase conjugated streptavidin.

7. BCIP/NBT — Add substrate and monitor the formation of colored spots.

LIMITATIONS OF THE PROCEDURE

- FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
- The kit should not be used beyond the expiration date on the kit label.
- Do not mix or substitute reagents with those from other lots or sources.
- Any variation in pipetting and washing techniques, incubation time or temperature, and kit age can cause variation in density of spots, intensity of specific staining and background level.

PRECAUTIONS

Some components of this kit contain sodium azide, which may react with lead and copper plumbing to form explosive metallic azides. Flush with large volumes of water during disposal.

Do not remove the flexible plastic underdrain on the bottom of the microplate before or during incubation and development since it may damage the PVDF membrane filters. The underdrain cover may be removed only after completing the incubation with BCIP/NBT chromogen.

Although the toxicity of the chromogenic substrate BCIP/NBT is not currently known, wear gloves to avoid contact with skin. Follow local, state and federal regulations to dispose of used BCIP/NBT.

MATERIALS PROVIDED

Human CD8α^+/IFN-γ Microplate (Part 893004) - One 96-well PVDF-backed microplate coated with anti-human CD8α^+ and anti-human IFN-γ monoclonal antibodies.

Detection Antibody Concentrate (Part 893005) - 150 μL of a 120X concentrated solution of biotinylated polyclonal antibody specific for human IFN-γ with preservatives.

Streptavidin-AP Concentrate A (Part 895358) - 150 μL of a 120X concentrated solution of Streptavidin conjugated to Alkaline Phosphatase with preservatives.

Dilution Buffer 1 (Part 895307) - 12 mL of a buffer for diluting Detection Antibody Concentrate with preservatives.

Dilution Buffer 2 (Part 895354) - 12 mL of a buffer for diluting Streptavidin-AP Concentrate A with preservatives.

Wash Buffer Concentrate (Part 895308) - 50 mL of a 10X concentrated solution of a buffered surfactant with preservatives.

BCIP/NBT Chromogen (Part 895867) - 12 mL of a stabilized mixture of 5-Bromo-4-Chloro-3′ Indolylphosphate p-Toluidine Salt (BCIP) and Nitro Blue Tetrazolium Chloride (NBT).

Human CD8α^+/IFN-γ Positive Control (Part 893006) - 1 vial (2 ng) of recombinant human IFN-γ; lyophilized.

STORAGE

Store the unopened kit at 2 - 8° C. Do not use beyond the kit expiration date. This kit is validated for single use only. Results obtained with opened/reconstituted reagents at a later date may not be reliable.

OTHER SUPPLIES REQUIRED

- Pipettes and pipette tips
- Deionized or distilled water
- Dulbecco's phosphate-buffered saline (PBS)
- Squirt bottle, manifold dispenser, or automated microplate washer
- 500 mL graduated cylinder
- 37° C CO_2 incubator
- Sterile culture media
- Dissection microscope or an automated ELISpot reader

TECHNICAL HINTS

- To minimize edge effect, place the microplate (bottom down) onto a piece of aluminum foil (about 4 x 6 inches). Add cells, cover the microplate with the lid and shape the foil around the edges of the microplate. The foil may be left on the microplate for the rest of the experimental procedure and removed after the BCIP/NBT has been washed off.
- Do not touch PVDF membrane filters with pipette tips when pipetting cells and reagents to avoid damage to the membrane.
- After completion of the experiment, do not dry the microplate at a temperature higher than 37° C since it may cause cracking of the PVDF membrane filters.
- The 96-well microplate provided in the kit is not sterile. However, due to the short incubation period and the presence of antibiotics in the culture media, microbial contamination has not been a problem during the ELISpot procedure.
- The kit is designed for single use only. The layout of the assay should be carefully planned to maximize the use of the plate and reagents provided.
- The controls listed are recommended for each ELISpot experiment.

    Positive Control - Use recombinant human IFN-γ.

    Unstimulated/Negative Control - Use the same number of unstimulated cells as stimulated cells.

    Background Control - Use sterile culture media.

    Detection Antibody Control - Substitute phosphate buffered saline for Detection Antibody.

REAGENT PREPARATION

Wash Buffer - If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. To prepare Wash Buffer, add 50 mL of Wash Buffer Concentrate to 450 mL of deionized water and mix well.

Human CD8α^+/IFN-γ Positive Control - Reconstitute lyophilized human IFN-γ with 250 μL of culture medium that is used to incubate cells.

Detection Antibody - Tap or vortex the vial to release reagent collected in the cap. Transfer 100 μL of Detection Antibody Concentrate into the vial labeled Dilution Buffer 1 and mix well. **For optimal performance, prepare Detection Antibody immediately before use.**

Streptavidin-AP - Tap or vortex the vial to release reagent collected in the cap. Transfer 100 μL of Streptavidin-AP Concentrate A into the vial labeled Dilution Buffer 2 and mix well. **For optimal performance, prepare Streptavidin-AP immediately before use.**

SAMPLE PREPARATION

The types of effector and responder cells used, method of cell separation, mode of stimulation, and length of incubation are to be determined by each investigator. R&D Systems' cell selection products are suitable for the purification of effector and responder cells. For a complete product listing of human, mouse, and rat cell selection products, see the R&D Systems catalog or visit our website at www.RnDSystems.com.

ASSAY PROCEDURE

Bring all reagents as needed to room temperature, except the Detection Antibody Concentrate and Dilution Buffer 1, which should remain at 2 - 8° C. All samples and controls should be assayed at least in duplicate. An Assay Record Template is provided at the back of this insert to record controls and samples assayed.

1. Fill all wells in the microplate with 200 μL of sterile culture media and incubate for approximately 20 minutes at room temperature.

2. When cells are ready to be plated, aspirate the culture media from the wells. Immediately add 100 μL of the appropriate cells to each well.

3. Incubate cells for 1 hour at room temperature on the benchtop.

4. Wash away cells which have not been captured by washing with PBS. Dump the contents into the sink and then fill with PBS and repeat two more times. **Do not aspirate cells.**

5. Add 100 μL of culture media containing the appropriate stimulant concentration and 100 μL of the appropriate controls (see Technical Hints for appropriate controls).

6. Incubate cells in a humidified 37° C CO_2 incubator. Optimal incubation time for each stimulus should be determined by the investigator. **Do not disturb the cells during the incubation period.**

7. Aspirate each well and wash, repeating the process three times for a total of four washes. Wash by filling each well with Wash Buffer (250 - 300 μL) using a squirt bottle, manifold dispenser, or autowasher. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
    Note: Adjust the height of the prongs of the manifold dispenser or autowasher to prevent damage to the membranes.

8. Add 100 μL of diluted Detection Antibody into each well and incubate at 2 - 8° C overnight.

9. Repeat step 7.

10. Add 100 μL of diluted Streptavidin-AP into each well and incubate for 2 hours at room temperature.

11. Repeat step 47.

12. Add 100 μL of BCIP/NBT Chromogen into each well and incubate for 1 hour at room temperature. **Protect from light**.

13. Discard the chromogen solution from the microplate and rinse the microplate with deionized water. Invert the microplate and tap to remove excess water. Remove the flexible plastic underdrain from the bottom of the microplate, wipe the bottom of the plate thoroughly with paper towels and dry completely either at room temperature (60 - 90 minutes) or 37° C (15 - 30 minutes).

CALCULATION OF RESULTS

The developed microplate can be analyzed by counting spots either manually using a dissection microscope or by using a specialized automated ELISpot reader. Specific spots are round and have a dark center with slightly fuzzy edges. Quantitation of results can be done, for example, by calculating the number of spot forming cells (SFC) per number of cells added into the well.

REPRODUCIBILITY DATA

Human PBMCs (5×10^6 cells/mL) were incubated for 1 hour at room temperature. Following three washes with PBS, stimulants (50 ng/mL of phorbol 12-myristate-13-acetate and 0.5 μg/mL calcium ionomycin) were added to the culture media and incubated overnight at 37° C in a 5% CO_2 incubator. The sample was assayed in eight wells according to the procedure and analyzed with a dissection microscope.

Well	Number of Spots Counted
1	164
2	173
3	177
4	167
5	170
6	181
7	171
8	177

TROUBLESHOOTING GUIDE

Observation	Problem	Corrective Action
Following the incubation with BCIP/NBT chromogen and rinsing the microplate with deionized water, the dark-blue background color of filter membrane attenuates visualization and quantitation of spots.	Wet membrane	Microplates cannot be analyzed accurately until PVDF filter membranes are completely dry. Wait until membrane becomes dry, usually 15 - 30 minutes at 37° C or 60 - 90 minutes at room temperature.
The number of spots in the wells that contained the cells is high but their contrast as well as intensity of staining in the Positive Control wells is low.	Underdevelopment - perhaps as a result of using Streptavidin-AP and/or BCIP/NBT solutions that have not been adjusted to room temperature	Bring the reagents to room temperature before adding to the wells.
The number of spots in the wells that contained cells is lower than expected whereas Positive Control wells turned black-blue.	Cell stimulation problem	Ensure that reagents used to stimulate the cytokine release from the cells retained their biological activity. One way to check is to perform immunocytochemistry on fixed cells after stimulation.
	Too few cells added to the wells	Increase the number of cells added per well.
Following incubation with BCIP/NBT and drying the microplate, the density of the spots makes it difficult to quantify them.	Too many cells were added to the wells	Make dilutions of cells (*i.e.,* 1×10^6, 5×10^5, 1×10^5, 5×10^4, 1×10^4 cells per well) to determine the optimal number of cells that will result in formation of distinct spots.

REFERENCES

1. Singer, A. and R. Bosselut (2004) Adv. Immunol. **83**:91.
2. Leahy, D.J. (1995) FASEB J. **9**:17.
3. Serafini-Cessi, F. *et al.* (1995) Adv. Exp. Biol. Med. **376**:135.
4. Sukhatme, V.P. *et al.* (1985) Cell **40**:591.
5. Norment, A.M. and D.R. Littman (1988) EMBO J. **7**:3433.
6. Spetz, A-L. *et al.* (1996) Am. J. Pathol. **149**:665.
7. Hartmann, J. *et al.* (1995) Eur. J. Immunol. **25**:2626.
8. Terry, L.A. *et al.* (1990) Tissue Antigens **35**:82.
9. Belz, G.T. *et al.* (2004) J. Immunol. **172**:1996.
10. Gangadharan, D. and H. Cheroutre (2004) Curr. Opin. Immunol. **16**:264.
11. Billiau, A. (1996) Adv. Immunol. **62**:61.
12. Pestka, S. *et al.* (2004) Immunol. Rev. **202**:8.
13. Kontsek, P. *et al.* (2003) Acta Virol. **47**:201.
14. Rinderknecht, E. *et al.* (1984) J. Biol. Chem. **259**:6790.
15. Pan, Y-C. E. *et al.* (1987) Eur. J. Biochem. **166**:145.
16. Dobeli, H. *et al.* (1988) J. Biotech. **7**:199.
17. Sakaguchi, M. *et al.* (1988) FEBS Lett. **230**:201.
18. Jarpe, M.A. and H.M. Johnson (1990) J. Immunol. **145**:3304.
19. Magazine, H.I. *et al.* (1988) Proc. Natl. Acad. Sci. USA **85**:1237.
20. Ahmed, C.M. *et al.* (2003) J. Cell Sci. **116**:3089.
21. Lortat-Jacob, H. and J-A. Grimaud (1992) Biochim. Biophys. Acta **1117**:126.
22. Sadir, R. *et al.* (1998) J. Biol. Chem. **273**:10919.
23. Langer, J.A. *et al.* (1994) Proc. Natl. Acad. Sci. USA **91**:5818.
24. Sugaya, M. *et al.* (1999) J. Invest. Dermatol. **113**:350.
25. Howie, S.E.M. *et al.* (1996) J. Invest. Dermatol. **106**:1218.
26. Battistini, L. *et al.* (1997) J. Immunol. **159**:3723.
27. Gupta, A.A. *et al.* (1996) J. Immunol. **157**:2123.
28. Neumann, H. *et al.* (1997) J. Exp. Med. **186**:2023.
29. Hoiden, I. and G. Moller (1996) Scand. J. Immunol. **44**:501.
30. Puddu, P. *et al.* (1997) J. Immunol. **159**:3490.
31. Yoshimoto, T. *et al.* (1997) Proc. Natl. Acad. Sci. USA **94**:3948.
32. Yeaman, G.R. *et al.* (1998) J. Immunol. **160**:5145.
33. Asea, A. *et al.* (1996) Clin. Exp. Immunol. **105**:376.
34. Briscoe, D.M. *et al.* (1997) J. Immunol. **159**:3247.
35. Lortat-jacob, H. *et al.* (1996) J. Biol. Chem. **271**:16139.
36. Arvilommi, H. (1996) APMIS **104**:401.
37. Schmittel, A. *et al.* (2000) J. Immunother. **23**:289.
38. Czerkinsky, C.C. *et al.* (1983) J. Immunol. Methods **65**:109.
39. Sedgwick, J.D. and P.G. Holt (1983) J. Immunol. Methods **57**:301.
40. Czerkinsky, C.C. *et al.* (1984) J. Immunol. Methods **72**:489.
41. Helms, T. *et al.* (2000) J. Immunol. **164**:3723.

ASSAY RECORD TEMPLATE

This template may be used as a record of samples and controls run in an assay.

04.06   751495.2   10/09